Cargando…
Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study
INTRODUCTION: Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with severe persistent allergic asthma. AIM: To demonstrate the quality of life in children with severe asthma and their c...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831278/ https://www.ncbi.nlm.nih.gov/pubmed/29507558 http://dx.doi.org/10.5114/ada.2017.71109 |